Search results for "HIV infection"

showing 10 items of 314 documents

Long-term outcomes of oral rehabilitation with dental implants in HIV-positive patients: A retrospective case series

2016

Background: The existing information on oral rehabilitations with dental implants in VIH-positive patients is scarce and of poor quality. Moreover, no long-term follow-up studies are available. Hence, the aims of this study were to describe the long-term survival and success rates of dental implants in a group of HIV-positive patients and to identify the most common postoperative complications, including peri-implant diseases. Material and Methods: A retrospective case series of HIV-positive subjects treated with dental implants at the School of Dentistry of the University of Barcelona (Spain) was studied. Several clinical parameters were registered, including CD4 cell count, viral load and…

Dental Restoration FailurePeri-implantitismedicine.medical_treatmentAlveolar Bone LossMEDLINEDentistryHIV InfectionsOdontologíaComplications (Medicine)Malalties de la boca03 medical and health sciences0302 clinical medicineMucositismedicineHumansDental Restoration Failure030212 general & internal medicineGeneral DentistryRetrospective StudiesDental ImplantsRehabilitationImplants dentalsbusiness.industryResearchDental implantsRetrospective cohort study030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseasePeri-ImplantitisCiencias de la saludTreatment OutcomeComplicacions (Medicina)Mouth diseasesOtorhinolaryngologySpainUNESCO::CIENCIAS MÉDICASSurgeryImplantOral SurgeryHIV-positive personsbusinessPersones seropositivesViral loadFollow-Up Studies
researchProduct

Biowaiver monographs for immediate-release solid oral dosage forms: Zidovudine (azidothymidine).

2012

Literature data on the properties of zidovudine relevant to waiver of in vivo bioequivalence (BE) testing requirements for the approval of immediate-release (IR) solid oral dosage forms containing zidovudine alone or in combination with other active pharmaceutical ingredients (APIs) are reviewed. Solubility, dissolution, and permeability data for zidovudine, along with its dosing schedule, therapeutic index and pharmacokinetic properties, and reports related to BE/bioavailability were all taken into consideration. Data for solubility and permeability suggest that zidovudine belongs to Class I according to the Biopharmaceutics Classification System. Also, zidovudine is not a narrow therapeut…

DrugAnti-HIV Agentsmedia_common.quotation_subjectPharmaceutical ScienceExcipientAdministration OralHIV InfectionsPharmacologyBioequivalenceDosage formPermeabilityCell LineExcipientsZidovudineDogsPharmacokineticsBIOEQUIVALÊNCIAMedicineAnimalsHumansmedia_commonActive ingredientbusiness.industryBiopharmaceutics Classification SystemSolubilityTherapeutic EquivalencyCaco-2 CellsbusinessZidovudinemedicine.drugJournal of pharmaceutical sciences
researchProduct

Monoclonal antibodies with subnanomolar affinity to tenofovir for monitoring adherence to antiretroviral therapies: from hapten synthesis to prototyp…

2020

Approximately 32 million people have died of HIV infection since the beginning of the outbreak, and 38 million are currently infected. Among strategies adopted by the Joint United Nations Programme on HIV/AIDS to end the AIDS global epidemic, the treatment, diagnosis, and viral suppression of the infected subjects are considered crucial for HIV prevention and transmission. Although several antiretroviral (ARV) drugs are successfully used to manage HIV infection, their efficacy strictly relies on perfect adherence to the therapy, which is seldom achieved. Patient supervision, especially in HIV-endemic, low-resource settings, requires rapid, easy-to-use, and affordable analytical tools, such …

DrugTenofovirAnti-HIV Agentsmedicine.drug_classmedia_common.quotation_subjectBiomedical EngineeringEnzyme-Linked Immunosorbent AssayHIV InfectionsMonoclonal antibody01 natural sciencesMice03 medical and health sciences0302 clinical medicineAcquired immunodeficiency syndrome (AIDS)medicineAnimalsHumansGeneral Materials Science030212 general & internal medicineTenofovirmedia_commonImmunoassaybiologyTransmission (medicine)business.industry010401 analytical chemistryAntibodies MonoclonalGeneral ChemistryGeneral Medicinemedicine.diseaseVirology0104 chemical sciencesImmunizationPoint-of-Care Testingbiology.proteinDrug MonitoringAntibodybusinessHaptenmedicine.drug
researchProduct

Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Devel…

2020

BACKGROUND: Sustainable Development Goal (SDG) 3 aims to "ensure healthy lives and promote well-being for all at all ages". While a substantial effort has been made to quantify progress towards SDG3, less research has focused on tracking spending towards this goal. We used spending estimates to measure progress in financing the priority areas of SDG3, examine the association between outcomes and financing, and identify where resource gains are most needed to achieve the SDG3 indicators for which data are available. METHODS: We estimated domestic health spending, disaggregated by source (government, out-of-pocket, and prepaid private) from 1995 to 2017 for 195 countries and territories. For …

Economic growthFinancing GovernmentPsychological interventionHIV Infectionsburden of disease030204 cardiovascular system & hematologyDISEASEALLOCATION0302 clinical medicineRA0421RA0421 Public health. Hygiene. Preventive MedicineSustainable developmentGlobal healthhealth economicsHealthcare FinancingHIV Infection030212 general & internal medicine10. No inequality11 Medical and Health SciencesDALYHealthy lives1. No povertyPublic Health Global Health Social Medicine and Epidemiology3rd-DASGeneral MedicineSustainable Development3. Good healthtuberculosisIMPOVERISHMENTTERRITORIESFinancingHumanFinancing PersonalResource (biology)Tuberculosi195 COUNTRIESDeveloping Countrie03 medical and health sciencesSDG 3 - Good Health and Well-beingAcquired immunodeficiency syndrome (AIDS)General & Internal MedicineSYSTEMATIC ANALYSISmedicineHumansBurden HIV/AIDS tubercolosis malariaHuman resourcesDeveloping CountriesSustainable developmentGovernmentAcquired Immunodeficiency SyndromeHealth economicsbusiness.industryDISABILITYCATASTROPHEGlobal Burden of Disease Health Financing Collaborator NetworkGLOBAL BURDENmedicine.diseaseMalariaSDG; health sector spending; development assistant for health.Health ExpenditureFolkhälsovetenskap global hälsa socialmedicin och epidemiologi3121 General medicine internal medicine and other clinical medicineNAHealth ExpendituresbusinessEXPENDITURE
researchProduct

Twenty Years of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Time to Reevaluate their Toxicity

2011

Twenty years of effective clinical application have consolidated non-nucleoside reverse transcriptase inhibitors (NNRTI) as essential components of the Highly Active Antiretroviral Therapy (HAART) employed in the treatment of Human Immunodeficiency Virus (HIV). However, as the disease has come under control, there has been growing emphasis on the long-term adverse effects induced by this chronic pharmacological therapy. Although traditionally considered to be safe and well-tolerated drugs, there is mounting evidence that associates NNRTI with the onset of cutaneous reactions, neuropsychiatric symptoms, hepatotoxicity, metabolic disturbances and gastrointestinal toxicity. Though the clinical…

EfavirenzNevirapineEtravirineHIV InfectionsDiseaseBiologyBioinformaticsBiochemistrychemistry.chemical_compoundDrug DiscoverymedicineAnimalsHumansDelavirdineAdverse effectPharmacologyReverse-transcriptase inhibitorOrganic Chemistryvirus diseasesHIV Protease InhibitorsHIV Reverse TranscriptaseClinical trialchemistryImmunologyHIV-1Reverse Transcriptase InhibitorsMolecular Medicinemedicine.drugCurrent Medicinal Chemistry
researchProduct

Mass loading, distribution, and removal of antibiotics and antiretroviral drugs in selected wastewater treatment plants in Kenya.

2020

The discharge of active pharmaceutical ingredients (APIs) into the aquatic environment from wastewater effluents is a concern in many countries. Although many studies have been conducted to evaluate the APIs removal efficiencies and emissions to the environment in wastewater treatment plants (WWTPs), most of these studies considered the aqueous and sludge phases, disregarding the suspended particulate matter (SPM) phase. To try to understand the role of the SPM, the occurrence of five most common antibiotics and three antiretroviral drugs (ARVDs) commonly used in Kenya were investigated in this study. APIs partitioning and mass loading in influents and effluents of three different WWTPs: tr…

Environmental Engineering010504 meteorology & atmospheric sciencesHydraulic retention timeTrickling filterlääkeainejäämätHIV Infectionsjätevesi010501 environmental sciencespharmaceuticalsWastewater01 natural sciencesMass loadingWaste Disposal FluidEnvironmental ChemistryHumansWaste Management and DisposalEffluent0105 earth and related environmental sciencesjäteveden käsittelyjätevedenpuhdistamotSewageenvironmental emissionantibiootitParticulatesPulp and paper industryPollutionsuspended particulate matterKenyaAnti-Bacterial Agentsnegative removal efficienciessludgelääkkeetWastewaterHigh massEnvironmental scienceSewage treatmentWater Pollutants ChemicalEnvironmental MonitoringThe Science of the total environment
researchProduct

Characterization of a novel population of low-density granulocytes associated with disease severity in HIV-1 infection

2012

The mechanisms resulting in progressive immune dysfunction during the chronic phase of HIV infection are not fully understood. We have previously shown that arginase, an enzyme with potent immunosuppressive properties, is increased in HIV seropositive (HIV+) patients with low CD4(+) T cell counts. Here we show that the cells expressing arginase in peripheral blood mononuclear cells of HIV+ patients are low-density granulocytes (LDGs) and that whereas these cells have a similar morphology to normal-density granulocyte, they are phenotypically different. Importantly, our results reveal that increased frequencies of LDGs correlate with disease severity in HIV+ patients.

Enzyme Metabolismlcsh:MedicineHIV InfectionsBiochemistryACTIVATION0302 clinical medicineImmunophenotypingImmunodeficiency VirusesRENAL-CELL CARCINOMAHIV SeropositivityMedicineSUPPRESSOR-CELLSlcsh:ScienceImmune ResponseCD180303 health scienceseducation.field_of_studyMultidisciplinarymedicine.diagnostic_testT Cellsvirus diseasesMiddle Aged3. Good healthEnzymesSEROPOSITIVE PATIENTSArginasemedicine.anatomical_structurePhenotypeHIV epidemiologyDisease ProgressionMedicineInfectious diseasesScience & Technology - Other TopicsNEUTROPHILResearch ArticleAdultGeneral Science & TechnologyT cellImmune CellsPopulationImmunologyCD18Viral diseasesGranulocytePeripheral blood mononuclear cellMicrobiologyFlow cytometryImmunophenotyping03 medical and health sciencesADHERENCEVirologyMD MultidisciplinaryHumanseducationBiology030304 developmental biologyScience & TechnologyArginasebusiness.industryTetraspanin 30MULTIDISCIPLINARY SCIENCESlcsh:RARGINASE-IHIVVirologyENDOTHELIAL-CELLSAntigens CD63ImmunologyLeukocytes Mononuclearlcsh:Qbusiness030215 immunologyGranulocytes
researchProduct

Rapid development of Epstein-Barr virus-associated Hodgkin's disease after cessation of foscarnet therapy in an HIV-infected patient.

2000

Epidemiological features suggest a link between Hodgkin's disease (HD) and Epstein-Barr virus (EBV) infection1. Indeed, EBV genome and expression of latent antigens can be found in Reed-Sternberg cells. In the majority of cases HD in HIV patients seems to be EBV-associated. We report on a 51-year-old HIV-infected patient in whom EBV-positive HD of mixed cellularity rapidly developed within one month after cessation of treatment with intravenous foscarnet.

FoscarnetMaleEpstein-Barr Virus InfectionsHIV InfectionsDermatologymedicine.disease_causeAntiviral AgentsVirusHerpesviridaehemic and lymphatic diseasesMedicineHumansPharmacology (medical)Sidabiologybusiness.industryPublic Health Environmental and Occupational HealthMiddle Agedmedicine.diseasebiology.organism_classificationEpstein–Barr virusVirologyHodgkin DiseaseLymphomaInfectious DiseasesFoscarnet SodiumImmunologyViral diseasebusinessmedicine.drugFoscarnetInternational journal of STDAIDS
researchProduct

Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection.

2017

Introduction RD1-based Interferon-γ Release Assays (IGRAs) cannot distinguish latent from active tuberculosis (TB) disease. Conversely, a positive response to heparin-binding haemagglutinin (HBHA)-based IGRAs, among TB-infected subjects, correlates with Mycobacterium tuberculosis (Mtb) containment and low risk of TB progression. The aim of this study was to characterize HBHA-immune responses in HIV-infected and uninfected subjects with active TB or latent TB infection (LTBI). Methods 49 subjects were prospectively enrolled: 22 HIV-uninfected (13 TB, 9 LTBI) and 27 HIV-infected (12 HIV-TB, 15 HIV-LTBI). Whole blood and peripheral blood mononuclear cells were stimulated with HBHA and RD1 anti…

Genetics and Molecular Biology (all)0301 basic medicineBacterial DiseasesRNA virusesCD4-Positive T-LymphocytesMalePhysiologylcsh:MedicineHIV InfectionsCD8-Positive T-LymphocytesPathology and Laboratory MedicineBiochemistryMemory T cellsWhite Blood CellsImmunodeficiency VirusesInterferonAnimal CellsImmune PhysiologyLectinsMedicine and Health SciencesProspective Studieslcsh:ScienceInnate Immune SystemMultidisciplinarybiologyT CellsInterleukinvirus diseasesMiddle AgedFlow Cytometry3. Good healthActinobacteriaInfectious DiseasesMedical MicrobiologyViral PathogensVirusesDisease ProgressionCytokinesFemaleCellular TypesPathogensmedicine.drugResearch ArticleAdultTuberculosisImmune CellsImmunologyCytotoxic T cellsEnzyme-Linked Immunosorbent AssayPeripheral blood mononuclear cellMicrobiologySettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICAMycobacterium tuberculosis03 medical and health sciencesInterferon-gammaImmune systemAntigenRetrovirusesmedicineTuberculosisHumansMicrobial PathogensAdult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; HIV Infections; Humans; Interferon-gamma; Lectins; Male; Middle Aged; Prospective Studies; Tuberculosis; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Blood CellsBacteriaLentiviruslcsh:ROrganismsBiology and Life SciencesProteinsHIVCell BiologyMolecular Developmentbiology.organism_classificationmedicine.diseaseTropical DiseasesVirology030104 developmental biologyAgricultural and Biological Sciences (all)Immune SystemImmunologylcsh:QInterferonsCD8Mycobacterium TuberculosisDevelopmental BiologyPLoS ONE
researchProduct

Predictors of therapy failure in newly diagnosed pulmonary tuberculosis cases in Beira, Mozambique.

2018

Abstract Objective Tuberculosis (TB) remains a major global health issue, ranking in the top ten causes of death worldwide. A deep understanding of factors influencing poor treatment outcomes may allow the development of additional treatment strategies, focused on the most vulnerable groups. Aims of the study were: (i) to evaluate the treatment outcome among TB subjects followed in an outpatient setting and (ii) to analyze factors associated with treatment failure in newly diagnosed patients with pulmonary TB in Beira, the second largest city of Mozambique. Results A total of 301 TB adult patients (32.6% females) were enrolled. Among them, 62 (20.6%) experienced a treatment failure over a 6…

Genetics and Molecular Biology (all)0301 basic medicineMaleTreatment outcomeAntitubercular Agentslcsh:MedicineHIV InfectionsSettore MED/42 - Igiene Generale E ApplicataBiochemistryTreatment failureBody Mass Index0302 clinical medicineTherapy failureOutpatientsGlobal healthOdds Ratio030212 general & internal medicineTreatment Failurelcsh:QH301-705.5MozambiqueCoinfectionGeneral MedicinePrognosisMozambique; Therapy failure; Tuberculosis; Biochemistry Genetics and Molecular Biology (all)Research NoteEducational StatusFemaleAdultEmploymentmedicine.medical_specialtyTuberculosisAdolescent030106 microbiologyNewly diagnosedGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesPulmonary tuberculosisInternal medicinemedicineHumansTuberculosislcsh:Science (General)PovertyTuberculosis PulmonaryAdult patientsbusiness.industrylcsh:RMalnutritionmedicine.diseaseTuberculosis Mozambique Therapy failurelcsh:Biology (General)Hiv statusbusinesslcsh:Q1-390BMC research notes
researchProduct